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Autoreactive 1-cells in Goodpasture's syndrome recognize the N-
terminal NC1 domain on a3 type IV collagen. Goodpasture's syndrome is
mediated by immunopathogenic autoantibodies to the cs3 NCI domain of
type IV collagen. It is not known whether collaborating T-cells participate
in this autoreactive response. Here we describe the first T-cell clone
isolated from a Goodpasture patient autoreactive to a3 type IV collagen
of glomerular basement membrane. To investigate cellular autoreactivity,
T-cells from Goodpasture patients or controls were isolated and stimulated by
purified native or recombinant type IV collagen proteins and synthetic
oligopeptides. Cell surface markers, the T-cell receptor repertoire, and
MHC-restriction were analyzed. T-cell clones specific for the a3(lV) NCI
domain were established in two Goodpasture patients, but not in controls.
One of the three CD8 T-cell clones was characterized further. It was MFTC
class I restricted (HLA-A11) and expressed the T-cetl receptor V 5.1. chain.
This clone specifically recognized a motif at the N-terminal area of the cs3(IV)
NC1 domain (AA 51 to 59: GSPATW]ITR). We conclude that autoreactive
T-cells exists in Goodpasture patients and may play a crucial role in the
inflammatoiy process. T-cell clones are autorcactive to the a3(IV) NC1
domain. At least for one of the clones, the T-cell epitopc is different from the
putative antibody-binding site.
Goodpasture's syndrome or anti-basement membrane antibody
mediated disease is an autoimmune disorder characterized by the
production of IgO autoantibodies against type IV collagen of
glomerular or alveolar basement membrane (GBM) [1]. Their
pathogenic relevance was clearly demonstrated by transfer exper-
iments, in which antibodies eluted from diseased human kidneys
were able to induce glomcrulonephritis in squirrel monkeys [21.In
addition, the disease may recur in human allografts, if circulating
antibodies are still present in the course of transplantation [3].
These anti-GBM antibodies are specifically targeted to the C-
terminal a3 NC1 domain of type IV collagen, which was recently
established as the Goodpasture autoantigen [4]. Type IV collagen
is the major constituent of mammalian basement membranes. It is
composed of six genetically distinct a(IV) chains (al-a 6) [5, 6].
The existence of the a3(IV) chain was verified by molecular
cloning of a cDNA that encodes the NC1 domain (232 residues)
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and a segment of the triple helical domain [7]. The Goodpasture
epitope, the combining site for the pathogenic autoantibodies, was
localized to the carboxyl-terminus of the NC1 domain of the
a3(IV) chain, encompassing the last 36 residues as the primary
interaction site [8].
Similar to other autoimmune disorders, such as in myasthenia
gravis, the B-cell autoantibody response is thought to result from
a disordered T-cell immunoregulatory control [9]. However, it is
not known whether or not autoreactive T-cells also play a
pathogenic role in Goodpasture's syndrome. Indirect evidence
derives from the detection of increased numbers of T-cells (both
CD4 and CD8) in the glomeruli of patients with crescentic
anti-basement membrane glomerulonephritis [101. Furthermore,
the strong association of HLA-DR and -DQ phenotypes with this
disease supports a role for autoreactive T-lymphocytes [11].
It was the aim of the present study to investigate cellular
immunity in Goodpasture's syndrome. We started to analyzed
T-cell immune responses in affected patients by using the C-
terminal NC1(IV) domain of type IV collagen from human
glomerular basement membrane as a candidate autoantigen.
Potentially autoreactive T-cells were characterized.
Methods
Antigens
The globular domain of human basement membrane type IV
collagen was prepared as described previously [12]. Briefly, gb-
merular (GBM), human placental (PBM) and intestinal (IBM)
basement membrane preparations were extracted with 6 M gua-
nidine-HCI, 0.05 M Tris-HCI (pH 7.5) for 12 hours and subse-
quently digested with bacterial collagenase (Boehringer, Mann-
heim, Germany) for 24 hours at 37°C. After passage through a DE
52 anion exchange column (2.5 X 40 cm), unbound material was
pooled, concentrated and applied to a Bio-Gel A-l.5 m (BioRad,
Munich, Germany) molecular sieve column. The purity of the
material was confirmed by SDS-PAGE and immunobbotting
against anti-type IV collagen cr1 chain antibody (Ab), anti-type IV
collagen cr3 chain Ab, as well as by human Goodpasture sera.
Bovine al(IV), a3(IV), and a5(IV) collagens were prepared
according to previously described methods [8]. Other antigens
used in the study were type IV collagen NC1 from EHS mouse
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sarcoma, tetanus toxoid (Behringwerke Marburg, Germany), rat
tail collagen type I and human placenta collagen type VIII (Sigma
Chemical Co., St. Louis, MO, USA). All these antigens were used
in a final concentration of 105g/ml in all tests. Recombinant
NC1(IV) fusion proteins [rcil (IV) NC1, ra2 (IV) Nd, ra3 (IV)
NC1, rcr4 (IV) Nd, and ra5 (IV) NC1] were further used as
antigens. Among the recombinant peptides two different ns3(IV)
proteins were analyzed: (1.) A truncated ra3(IV) protein lacking
part of the N-terminal NC1(IV) domain (deletion of the first 14
amino acids of the NC1 domain = 218 residues), (2.) An
elongated ra3(IV) NC1 protein (232 residues of the complete
NC1 domain plus 12 residues of the triple helical domain).
Plasmid Construction, expression and purification were reported
previously [13]. Briefly, cDNA encoding the NC1 domains of
human type IV collagen were expressed in E. coli as fusion
proteins using the pDS-MCS vector. Purity of expressed proteins
was determined on 5 to 22% SDS-PAGE gradient gels using
Coomassie Blue staining. In all tests the recombinant proteins
were used in concentrations of i0, 106, and 107g/ml. Oh-
gopeptides from the NC1(IV) domain of human a3(IV) type IV
collagen, prepared and purified as described previously [8], were
screened for the ability to induce T-cell proliferation. Further-
more, HLA-Al 1 specific motifs were subsequently synthesized
and tested in final concentrations of 108, io— and 1010g/ml in
all assays.
Human type IV collagen NC1 (IV)-specific T-cell lines and clones
Mononuclear cells (PBMC) were obtained from peripheral
blood by Ficoll-Hypaque (Pharmacia LKB Biotechnology, Mil-
waukee, WI, USA) density gradient centrifugation. Donors in-
cluded two patients with Goodpasture's syndrome (B.F., HLA-
phenotype, A2 All B7 Bw62 Bw6 Cw3 DR2 DRw15 DRw8
DRw52 DQw1; and E.V., HLA-phenotype, A2 A19 B7 B21 Bw4
Bw6 DR2 DR4 DRw 52 DQw2), three patients with anti-GBM
antibody negative, ANCA positive crescentic glomerulonephritis
(P.F., B.N., K.S.) and two healthy volunteers (M.S., O.P.). Both
patients with Goodpasture's syndrome presented with rapidly
progressive glomerulonephritis and pulmonary hemosiderosis.
Light microscopy showed diffuse glomerulonephritis with endo-
capillary proliferation, tubulointerstitial disease and glomerular
crescent formation in 80% (B.F.) or in 75% (E.V.), respectively.
Linear staining for IgG could be demonstrated in both patients.
Both received plasma exchange (for 5 days) combined with
steroids (250 mg methyl-prednisolone for 3 days, followed by 1
mg/kg/body wt) and cyclophosphamide (1.5 mg/kg/body wt). Cells
were obtained three to four weeks after the initial presentation of
symptoms. The lymphocytes were thus characterized shortly after
the initiation of therapy. They were cultured in RPM! 1640
(Gibco BRL Life Technologie, Eggenstein, Germany) containing
L-glutamine, 25 mi Hepes (Gibco), 100 U/ml penicillin G, 100
ig/ml streptomycin (Gibco), 10% pooled human AB serum
(supplied by BRK, Nurnberg, Germany) and 10 g/ml human
GBM type IV collagen NC1(IV) at 37°C in 5% CO2. In order to
remove cell debris cells were collected and separated by Ficoll
density gradient on day 10 and 21. They were then restimulated
with autologous irradiated (3OGy) PBMC (5 >< iO cells/well) and
10 ag/ml NC1 type IV collagen. After three days of culture 5 U/mI
of human rIL-2 (Eurocetus, Frankfurt, Germany) were added.
Proliferative response with or without 10 jsg/ml NC1(IV) was
tested by 3H-thymidine incorporation. NC1(IV)-specific T-cell
lines were purified and cloned by limiting dilution. Cell numbers
ranged from 10 to 0.5 per well. Autologous irradiated PBMC (5 X
104/well), 10 jsg/ml NC1(IV) and 50 U/ml human rIL-2 added
after three days of culture were used for stimulation. Cloned cells
were washed, split and tested again for their proliferative response
to NC1(IV).
Proliferation assay
Antigen induced proliferation was examined by 3H-thymidine
incorporation assay after 72 hours of culture. Prior to testing, cells
were cultured for two to three days without NC1(IV), rIL-2 or
autologous irradiated PBMC. All antigens (that is, proteins,
oligopeptides and nonamers) used in the study were coincubated
with autologous irradiated lymphocytes, cultured for 72 hours,
and then tested.
For the analysis of MHC restriction, antigen-presenting cells
from healthy donors with known HLA-types and MHC class I
specific mAb (anti-HLA-A2, anti-HLA-A11, and anti-HLA-B7;
Pasteur Merieux S.V,, Lyon, France) were used. Cells were
harvested onto glass fibre filters using the PHD cell harvester
(Cambridge Technology Inc., Watertown, MA, USA). The incor-
porated radioactivity was assessed by liquid scintillation counting.
For better comparison, results are expressed as stimulation index
(SI = cpm cells plus antigen/cpm cells without antigen).Positive
result range from 7.5 to 19.5 x i0 cpm, negative results range
from 0.5 to 1.5 >< iO cpm.
T-cell phenotype analysis
Cells (1 >< 10) were stained with the following FITC- or
Phycoerythrine (PE)-conjugated mouse anti-human F(ab')2
monoclonal antibodies at 4°C for 30 minutes: CD4/CD8; CD45 RA;
CD45 RO; CD2; and a/ T-cell receptor (Immunotech SA, Mar-
seille, France). Fluorescence was measured using the FACScan®
(Becton Dickinson & Co., Heidelberg, Germany). T-cehl receptor
VJ3 chain nucleotide sequence was determined by PCR amplifi-
cation of eDNA as previously described [14]. Briefly, oligo-(dT)-
primed cDNA was sythesized from 1 jsg of extracted RNA (Quick
Prep® mRNA purification kit; Pharmacia LKB, Milwaukee, WI,
USA). For PCR amplification of T-cell receptor variable regions
28 different V oligonucleotide primers were used (V 1, V/3 2,
V 3, V13 4, V 5.1, V 5.2 to 3, V 6.1 to 3, V 6.7, V 7, V13 8.1
to 2, V 9, Vf3 10, V3 11, V3 12, V l2aE, Vf3 13.1, V13 13.2, V
14, V 15, Vp 16, Vp 17, V 18, vp 19, V 20, V 21, V 22, V
23, V 24). The cDNAs were amplified using Taq polymerase
(Boehringer) and standard reaction conditions according to sug-
gestions of the manufacturer (Perkin-Elmer Cetus Corp., Nor-
walk, CT, USA). Thirty-five PCR cycles were performed (dena-
turation at 94°C for 1 mm, annealing at 55°C for 1 mm, and
extension at 72°C for 1 mm). The amplified products were
subjected to electrophoresis on 1.5% agarose gel and transblotted
onto nitrocellulose membranes. Blots were hybridized with 32P-
labeled TCRj3 constant region-specific oligonucleotide probes.
TcR insert DNA was subcloned into plasmid vector pTZI8R
(Pharmacia, Freiburg, Germany) and sequenced by the chain
termination technique using universal, reverse and TCR V and C
element-specific primers.
Results
Two patients with Goodpasture's syndrome (B.F., E.V.), three
with anti-GBM antibody negative, ANCA positive, crescentic
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Fig. 1. Flow histogram demonstrating cell swfrice expression of CD8, CD45RO and a/3 T-cell receptor on T-cell clone BF-13. Fluorescence was measured
after labeling with monoclonal FITC- or Phycoerythrine conjugated mouse anti-human F(ab') monoclonal antibodies at 4°C for 30 minutes: CD4/CD8;
CD45RA; CD45RO; and a/f3 T-cell receptor (Immunotech SA, Marseille, France). Fluorescence was measured using the FACScan® (Becton Dickinson
& Co., Heidelberg, Germany).
glomerulonephritis (P.F., B.N., K.S.) and two healthy volunteers
were screened for T-eells, which proliferate in response to the
C-terminal NC1 domain of GBM type IV collagen. Antigen
restricted T-cell lines could only he established from patients with
Goodpasture's syndrome. The stimulation index (SI) in their
proliferation assay varied between 2.8 and 10.5 (data not shown).
In contrast, no T-cells responding to NC1(IV) could be found in
patients with crescentic glomerulonephritis due to ANCA positive
systemic necrotizing vasculitis or in healthy volunteers.
Characterization of NCI (IV)-specijic T-cell clones (TCC)
T-cclls responding to NCI(IV) were further cloned by limiting
dilution. Proliferating cells were characterized according to their
surface marker proteins, their T-cell receptor, and their MHC
restriction. From the two patients with Goodpasture's syndrome
three different T-cell clones were phenotyped by FACS. They all
were CD8, CD45R0, and TCR aI (Fig. 1). Cells respond to
stimulation by the glomerular NCI(IV) domain and to the
recombinant a3(IV) NC1 protein (Table 1). The one with the best
stimulating response, T-cell clone BF-C13, was characterized
further. Cloning and DNA-sequencing of the amplified T-cell
receptor Vp-chain gene indicated the expression of the V 5.1
chain by the isolated T-cell clone (Fig. 2). Proliferative response
to antigen was most active in association with the class I allel
HLA- All (Fig. 2). It was reduced by preincubation with an
anti-HLA-All specific antibody in a dose-dependent matter. In
contrast, anti-I-ILA-A2 and anti-HLA-B7 were without effect.
T-cell epitope
The established T-eell clone (BF-C13) was tested for respon-
siveness to various antigens. Tetanus toxoid, collagen type 1 and
collagen type VIII were used as negative controls. NC1(IV) from
human placenta, human small intestine and mouse EHS sarcoma
cell line [al(IV) and a2(IV) chain] were used in comparison to
Table 1. Patient screening for T-cells
BF C13 BF C20 EV C18 PF BN KS
0 1.4 0.7 1.3 0.8 1.0 0.4 0.9 0.81 0.9
Collagen 1 1.2 0.9 1.1 1.0 1.1 0.8 0.87 0.93 0.94
NCI(IV) 15.8 4.1 12.5 5.7 10.7 3.1 0.95 0.84 0.92
al(IV) 0.9 0.7 1.0 0.9 1.3 1.1 nd nd nd
a3(IV) 14.4 3.3 10.7 2.8 7.9 2.1 nd nd nd
a5(IV) 1.2 1.3 1.4 0.8 1.1 0.8 nd nd nd
Two patients with Goodpasture's syndrome (B.F., E.V.), and three with
anti-GBM antibody negative, ANCA positive, crescentic glomerulone-
phritis (P.F., B.N., KS.) were screened for T-cells, which proliferate in
response to the C-terminal NCI(TV) domain of GBM, in response to
collagen type I, and to the recombinant cxl(IV) NC1, a3(IV) Nd, and
cs5(IV) NC1 proteins. T-cell proliferation was examined by 3H-thymidine
incorporation assay after 72 hours of culture. The incorporated radioac-
tivity was assessed by liquid scintillation counting. Results are expressed as
mean cpm >< iO sD of triplicate culture (N = 5). No T-cells responding
to the antigens tested could be established in patients with crescentie
glomerulonephritis due to ANCA positive systemic vasculitis. In these
patients T-cell stimulation by recombinant proteins has not been done
(nd).
NC1(IV) from GBM a1(IV) to a6(IV) chain, Figure 3A].
Recombinant NCI(IV) domains of tsl(IV), cs2(IV), cs3(IV),
a4(IV), and a5(IV) proteins were also used as antigens to clarify
T-cell specificity. Proliferation could only be induced by the full
length recombinant cs3(IV) NC1 protein (Fig. 3b, N = 5, 10 and
10 7g/mI). The truncated recombinant a3(IV) Nd protein
(218AA) stimulated the TCC in a lesser degree only when using
higher concentrations (10 and io glml, Fig. 4A). When we
used biochemically-purified bovine cs3(IV) NC1 with great homol-
ogy to human cs3(IV) NC1, we tried to prove the results obtained
with recombinant proteins. T-cell proliferation was stimulated in
a minor degree (SI 3.5) when using higher concentrations (l0
g/ml). Bovine ai(IV) and cx4(IV) chains did not stimulate the
AntijD4 Anb-CD8
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Fig. 2. MHC-class I restriction and T-cell
receptor chain nucleotide and deduced
aminoacid sequence of the T-cell clone BF-C]3.
(A) For the analysis of MHC restriction,
antigen-presenting cells from healthy donors
with known HLA-types and MHC class I
specific mAb (anti-HLA-A2, anti-HLA-A 11,
and anti-HLA-B7; Pasteur Mcrieux S.V., Lyon,
France) were used. The proliferation was
evaluated by 3H-thymidine incorporation assay
after 72 hours of culture. Proliferative response
was reduced by preincubation with an anti-
HLA-A1 1 specific antibody in a dose-dependent
matter. In contrast, anti-HLA-A2 and anti-
HLA-B7 were without effect. (B) T-cell
receptor V chain nucleotide sequence was
determined by PCR amplification of the eDNA.
For the PCR amplification of T-ccll receptor
variable regions 28 different V oligonucleotid
primer pairs were used.
TCC (Fig. 3C). These data support the conclusion that the T-cell
epitope of the established autoreactive T-cell clone is located on
the a3(IV) chain of type IV collagen. Synthetic oligopeptides and
a series of nonarner peptides with HLA-A11 specific motifs were
used to locate the T-cell epitope for this clone. A proliferative
response could be induced with the N-terminal a3(IV) NC1 peptide
GLKGKRGDSGSPA TWTTR (42 to 59, final concentration: I 09g/
ml), whereas the other peptides were unable to stimulate the TCC
(Fig. 3C). This observation was further confirmed by using the
HLA-A1 1 specific nonamer 51 to 59 GSPA TWTTR (final concentra-
tion: 10 10g/ml) that also induced a T-cell response. The other
peptides tested (57 to 65: TTRGFVFTR; 88 to 96: FLFVQGNQR;
101 to 111:DLGTLGSCLQR; 121 to 131: NVNDVCNFASR; 145 to
154: PMNMAPIIGR; 247 to 255: WLASLNPER; 250 to 259:
SLNPERNFRK; 264 to 272: TVKAGELEK) were without effect.
Discussion
Production of either antibodies that react with host tissue or
immune effector T-cells that are autoreactive to self-peptides
characterize most autoimmune diseases. T-cells have been shown
to be pathogenically relevant in multiple sclerosis [15], autoim-
mune thyroid disease [16], and rheumatoid arthritis [171. In
myasthenia gravis autoantibodies to the acetylcholine receptor
produced by B-cells are of pathogenic relevance. However, disor-
dered T-cell function appears to be of critical importance in this
ture's syndrome is also caused by pathogenic relevant autoanti-
bodies that are directed to the a3(IV) NC1 domain of type IV
collagen. Whether or not cellular immunity plays a role in the
pathogenesis of this disease has not been investigated. Evidence
for a critical role of cell mediated immunity also in Goodpasture's
syndrome can be deduced from experimental animal models. For
example, bursectomized chickens immunized with heterologous
GBM in adjuvant developed nephritis even in the absence of
detectable autoantibodies [19]. In addition, the disease could be
induced in naive syngeneic SC chickens simply by passive transfer
of T lymphocytes [20]. Furthermore, in a rat model of experimen-
tal anti-GBM glomerulonephritis activation of the cell-mediated
immune system was evidenced by delayed type hypersensitivity to
the immunizing antigen [21]. The development and severity of the
disease in this model were not associated with antibody produc-
tion alone. A role for T-cells in this particular and other animal
models [22] is further supported by immunohistochemical dem-
onstration of mononuclear cell-infiltrates in diseased kidneys.
Comparable infiltrates have also been shown in human Goodpas-
ture's syndrome. Taken together, these data strongly suggest a
role for autoreactive T-cell in this autoantibody mediated disease.
In our study, mononuclear cells were obtained from peripheral
blood of Goodpasture patients and stimulated by human GBM
A
B
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disease, too [18]. Glomerulonephritis in autoimmune Goodpas-
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type IV collagen NC1 (IV) as candidate autoantigen. Proliferating
cells were subsequently cloned by limiting dilution. Three T-cell
clones could be established that all responded to the C-terminal
NC1 domain of GBM type IV collagen. Proliferation could also
be induced in these T-cell clones by recombinant a3(IV) NC1
protein. In contrast, no response to NC1(IV) from human pla-
centa, human small intestine and mouse EHS sarcoma cell lines
could be induced. Also recombinant al(IV), a2(IV), a4(IV) and
is5(IV) proved to be ineffective. These results strongly suggest,
that a3(IV) NC1 harbours the T-cell epitope.
For more detailed studies, the phenotype of T-cell clone
BF-C13 was analyzed. Cells were CD8 and CD45R0. The
CD45 molecule displays phosphotyrosine phosphatase activity
and plays a critical role in regulating T-cell receptor (TcR)
mediated signals. CD45 R0 populations are thought to be
memory cells, but some of the CD45 R0 cells express markers
characteristic of recently activated T-cells [23] The aII3 TcR of
the T-eell clone BF-C13 expressed the VJ3 5,1 TcR chain on its
surface. Generally, the T-cell receptor determines the repertoire
of antigen-reactive T-cells and might be critically involved in the
maintenance of peripheral tolerance to autoantigens [24]. The
TcR V/3 chain in the established T-cell clone BF-C13 was primary
sequenced to prove that the cells were of clonal origin. It is not
known, whether the V 5.1 chain is of importance for the
development of the Goodpasture's syndrome. Since there are only
few data on the T-cell receptor V3 chain expression in Goodpas-
ture's syndrome, it is impossible to say whether any chain is
preferentially expressed in the state of disease.
MHC restriction analysis showed that response to antigen by
the CD8 TCC BF-C13 was induced in conjunction with the class
I allele HLA-A1 1. HLA DR2 association with Goodpasture's
syndrome has previously been described [25] and was confirmed
recently by using sequence-specific oligonucleotide probes [11,
26]. Especially the DR2 allele DRB1-1501 seems to be associated
with disease (21 out of 23 patients). This HLA class II phenotype
could also be demonstrated in the donor of the established T-cell
clone. A close association with the class I allele HLA-A1 1 and the
Goodpasture's syndrome has not been described. Furthermore, it
remains unclear why all the clones raised were rather CD8 than
CD4 positive. It might be due to the fact that cells were estab-
lished after the initiation of therapy. Moreover, it cannot be
excluded that it is the result of the cloning technique.
In order to characterize the target antigen of the T-cell clone
BF-C13, we used different approaches. By comparing the prolif-
erative response to two recombinant a3(IV) NCI proteins, which
differed in the number of residues, the region of interest could be
mapped to the N-terminal area of the a3(IV) NC1 domain. We
were able to show that strong proliferation could be induced by
the full length ra3(IV) NC1 domain, while a truncated protein that
lacks the N-terminal 26 amino acids was ineffective. We therefore
speculated that likely in this area the T-cell epitope might be located.
This hypothesis was further supported by testing several oligopep-
tides, designed with respect to major differences of the a3(IV) chain
compared to the csl-a5(IV) chains. Since T-lymphocytes respond to
self- or foreign peptides only in conjunction with MHC, additionally
peptides with HLA-A1 1 specific motifs identified within the cs3(IV)
NC1 aminoacid sequence were included in our study. The HLA-A11
specific nonamer GSPA TW7TR that is located within the N-terminal
area of the cs3(IV) NC1 domain induced proliferation in this
particular T-celI clone. Therefore by combining the two different
approaches, the N-terminal area of the cs3(IV) NC1 domain is
considered to be the T-cell epitope at least in this clone. The epitope
is slightly different from the putative antibody-binding side [8].
In conclusion, our findings demonstrate that the three estab-
lished T-cell clones are autoreactive to the n3(IV) NC1 domain of
type IV collagen. For the first time a proliferating T-cell clone
(BF-C13) could be established to localize the T-cell epitope at
A
B
r-NC1 al(IV)
r-NC1 x2(IV)
r-NC1 ct3(IV)
r-NC1 a4(IV)
r-NC1 a5(IV)
C
b-Nd cxl(IV)
b-NC 1 cx3(IV)
b-NC 1 ci4(IV)
SI
Fig. 3. (A) The T-cell clone BF-C13 was examined for antigen induced
T-cell proliferation in a 3H-thymidine incorporation assay after 72 hours of
culture. Prior to testing, cells were cultured for 2 to 3 days without antigen,
rIL-2 or autologous irradiated PBMC. The incorporated radioactivity was
assessed by liquid scintillation counting. For better comparison, results arc
expressed as stimulation index (SI = epm cells plus antigen/epm cells
without antigen). Type IV collagen NC1(IV) from EHS mouse sarcoma,
tetanus toxoid, rat tail collagen type I and human placenta collagen typ
VIII were used as negative control. All antigens were tested in a final
concentration of 1O glml. (B) Reactivity of recombinant collagen type
IV NCI proteins on antigen induced proliferation. Among the five
a-chains tested, only r-NC1-a3(IV) induced T-cell proliferation. (C) The
mitogenic effects of bovine al(IV), a3(IV) and a4(IV) NC1 proteins were
tested. Again only bovine NC1-a3(IV) induced T-cell proliferation.
1132 Merkel et al: Autoreactive T-cells in Goodpasture's syndrome
least for this clone. Though these data have to be supported in
further studies, they add substantially to our understanding of the
pathogenesis of this disease. Goodpasture's syndrome therefore
might be considered an autoimmune disorder in which activated
T-cells participate apart from the well-known B-cell antibody
response. This further suggests that drugs like cyclosporine A,
which inhibit T-cell proliferation, more specifically might be of use
in Goodpasture's syndrome. Moreover, future immunotherapy
might include antigen-specific suppression of the immune re-
sponse based on the knowledge of the antigenic epitope recog-
nized by the T-cell receptor in patients with Goodpasture's
syndrome. A comparable approach has already been used in
multiple sclerosis [27] and in rheumatoid arthritis [28] where oral
administration of the candidate autoantigen was used for induc-
tion of antigen specific tolerance.
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Fig. 4. Epitope mopping. (A) The T-cell clone
BF-C13 was tested for oligopeptide induced
proliferation by 3H-thymidine incorporation
assay after 72 hours of culture. Various
peptides and two different r-NC1 cs3(IV)
proteins were tested. Only the full length NCI
cs3(IV) protein (232 + 12 amino acids = AA)
and the oligopeptide AA 42 to 59 stimulated
the TCC. The incomplete r-NC1 a3(IV) protein
(218 AA) lacks part of the N-terminal NC1
domain including the AA 42 to 59 and is thus
ineffective in stimulating the T-cell clone. (B)
Oligopeptides with HLA-A1 1 specific motifs
•COOH were used to induce proliferation. Only the
peptide 51 to 59 derived from the N-terminal
284AA NC1 domain stimulated T-cell proliferation.
Reprint requests to Prof Dr. Manfred Weber, Medical Clinic I, Hospital
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